Copyright (c) 2020 Mila Juni Asti
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Nanoparticle Bitter Melon (Momordica Charantia L.) as the Effort to Reduce Fasting Plasma Glucose in Menopause Women with Type 2 Diabetic Mellitus
Corresponding Author(s) : Mila Juni Asti
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 7 No. 2 (2019): 2019 Volume 7- Issue -2
Abstract
Background
Clinically, the case of diabetic mellitus type two is the highest case of diabetic mellitus found, accounting there are > 90% of all diabetic cases. One of medicinal treatment of non pharmacology can be done is consume bitter melon. Bitter melon (momordica charantia L.) has antidiabetic and hypolipidemic activity so that it can be used coincide with chemical drugs to treat diabetic as well as inhibit diabetic complications. Nanoparticle are a technology that aims to make sizes (dosage forms) in range of 10nm-1000nm.
Objective
To prove that of nanoparticle bitter melon (momordica charantia L.) can reduce fasting plasma glucose in menopause women with type 2 diabetic mellitus for 30 days in the intervention group and the control group.
Methods
True experiment: with pretest - posttest control group design. The population is menopause women with diabetes mellitus type 2 who participated the prolanis program at the community health center Keruak. Sample technique use is simple random sampling. The sample consist of 30 respondents, each group consisted of 15 respondents. Each group was given the intervention for 30 days. The intervention group was given nanoparticle bitter melon (a daily dose of 1 gram) plus metformin (a daily dose of 1 gram), while the control group was only given metformin with a daily dose of 1 gram.
Results
The difference between the intervention group is 102,46 mg/dL with p value 0.000 and the control group is 20,47 mg/dL with p value 0.005.
Conclusion
Nanoparticle bitter melon (momordica charantia L.) can be used as an effort to decrease fasting plasma glucose in menopause women with diabetes mellitus type 2.